DK3082831T3 - Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol - Google Patents
Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol Download PDFInfo
- Publication number
- DK3082831T3 DK3082831T3 DK14827505.0T DK14827505T DK3082831T3 DK 3082831 T3 DK3082831 T3 DK 3082831T3 DK 14827505 T DK14827505 T DK 14827505T DK 3082831 T3 DK3082831 T3 DK 3082831T3
- Authority
- DK
- Denmark
- Prior art keywords
- cyclodextrins
- diseases
- prevention
- methyl
- concentration
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 229920000858 Cyclodextrin Polymers 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- 229940097362 cyclodextrins Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1362633A FR3014694B1 (fr) | 2013-12-13 | 2013-12-13 | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| PCT/FR2014/053309 WO2015087016A1 (fr) | 2013-12-13 | 2014-12-12 | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3082831T3 true DK3082831T3 (da) | 2021-04-12 |
Family
ID=50424476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14827505.0T DK3082831T3 (da) | 2013-12-13 | 2014-12-12 | Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10022392B2 (da) |
| EP (2) | EP3581188A1 (da) |
| JP (2) | JP6322289B2 (da) |
| KR (3) | KR102453643B1 (da) |
| CN (2) | CN110123831A (da) |
| AU (2) | AU2014363270B2 (da) |
| BR (1) | BR112016013481A2 (da) |
| CA (2) | CA3180528A1 (da) |
| DK (1) | DK3082831T3 (da) |
| ES (1) | ES2859609T3 (da) |
| FR (1) | FR3014694B1 (da) |
| MX (2) | MX381039B (da) |
| PL (1) | PL3082831T3 (da) |
| RU (1) | RU2677889C1 (da) |
| WO (2) | WO2015087017A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014022841A1 (en) | 2012-08-03 | 2014-02-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Cyclodextrin for the treatment of lysosomal storage diseases |
| CA2988529A1 (en) | 2015-06-10 | 2016-12-15 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| FR3042501B1 (fr) * | 2015-10-16 | 2017-11-03 | Roquette Freres | Nouvelles cyclodextrines methylees et leurs procedes de preparation |
| US20200000840A1 (en) * | 2016-03-20 | 2020-01-02 | Asdera Llc | Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders |
| MX2019000342A (es) * | 2016-07-08 | 2019-09-04 | Ranedis Pharmaceuticals Llc | Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas. |
| KR101906578B1 (ko) * | 2017-07-28 | 2018-10-10 | 경북대학교 산학협력단 | 사이클로덱스트린 및 vegf 과발현 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물 |
| CA3076821A1 (en) | 2017-09-28 | 2019-04-04 | Asdera Llc | Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation |
| CN107982546A (zh) * | 2017-12-05 | 2018-05-04 | 中国药科大学 | 基于主客体相互作用的酸敏感超分子纳米粒及其应用 |
| WO2019173283A1 (en) | 2018-03-05 | 2019-09-12 | Marquette University | Method and apparatus for non-invasive hemoglobin level prediction |
| CN108342473A (zh) * | 2018-04-13 | 2018-07-31 | 东华大学 | 一种用于检测血脂代谢相关基因abcg1甲基化的试剂盒 |
| FR3083234B1 (fr) * | 2018-06-29 | 2020-11-27 | Roquette Freres | Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation |
| MX2020013689A (es) * | 2018-06-29 | 2021-05-12 | Roquette Freres | Hidroxipropil-?-ciclodextrina novedosa y proceso para la producción de esta. |
| US11925659B2 (en) | 2018-10-29 | 2024-03-12 | Cyclo Therapeutics, Inc. | Methods for treating Alzheimer's disease |
| JP7607935B2 (ja) | 2019-01-03 | 2025-01-06 | サイクラリティ・セラピューティクス・インコーポレイテッド | シクロデキストリン二量体、それらの組成物、及びそれらの使用 |
| US11446325B2 (en) * | 2020-09-30 | 2022-09-20 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases |
| FR3115682B1 (fr) * | 2020-11-05 | 2023-02-24 | Roquette Freres | Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique |
| WO2023156966A1 (en) | 2022-02-18 | 2023-08-24 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
| CN118715017A (zh) * | 2022-02-18 | 2024-09-27 | 贝伦治疗公益公司 | 用2-羟基丙基-β-环糊精治疗高甘油三酯血症 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62265230A (ja) * | 1986-05-12 | 1987-11-18 | Kao Corp | 高脂血症治療・予防剤 |
| BE1006873A6 (nl) * | 1993-03-26 | 1995-01-10 | Merkus Franciscus W H M | Toedieningsformulering voor nasale insuline toediening. |
| CA2311356C (en) | 1998-01-28 | 2004-07-13 | Warner-Lambert Company | Method for treating alzheimer's disease |
| EP1272531B8 (en) | 1999-11-12 | 2007-02-14 | Roquette Frˬres | Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds |
| AU2001253727A1 (en) * | 2000-04-21 | 2001-11-07 | The Trustees Of Columbia University In The City Of New York | Methods for identifying compounds useful for preventing acute clinical vascular events in a subject |
| AUPR178300A0 (en) * | 2000-11-29 | 2000-12-21 | Heart Research Institute Ltd., The | Cyclodextrins and reversal of atherosclerosis |
| TW200307011A (en) * | 2002-04-18 | 2003-12-01 | Chugai Pharmaceutical Co Ltd | Hyaluronic acid modifier |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| AU2005272578A1 (en) * | 2004-08-13 | 2006-02-23 | Angiotech International Ag | Compositions and methods using hyaluronic acid and hyluronidase inhibitors |
| GB0421176D0 (en) | 2004-09-23 | 2004-10-27 | Poston Robin | Treatment of atherosclerosis |
| US9034846B2 (en) * | 2004-10-10 | 2015-05-19 | Universite De Liege | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases |
| EP1655034A1 (en) * | 2004-10-10 | 2006-05-10 | Université de Liège | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases. |
| US7879821B2 (en) * | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
| TW201006463A (en) * | 2008-06-26 | 2010-02-16 | Merz Pharma Gmbh & Co Kgaa | Pharmaceutical compositions comprising aminocyclohexane derivatives |
-
2013
- 2013-12-13 FR FR1362633A patent/FR3014694B1/fr active Active
-
2014
- 2014-12-12 US US15/039,864 patent/US10022392B2/en active Active
- 2014-12-12 CN CN201910316561.5A patent/CN110123831A/zh active Pending
- 2014-12-12 RU RU2016128411A patent/RU2677889C1/ru active
- 2014-12-12 EP EP19184268.1A patent/EP3581188A1/fr active Pending
- 2014-12-12 CN CN201480065300.6A patent/CN105792833B/zh active Active
- 2014-12-12 JP JP2016538683A patent/JP6322289B2/ja active Active
- 2014-12-12 MX MX2016007658A patent/MX381039B/es unknown
- 2014-12-12 CA CA3180528A patent/CA3180528A1/fr active Pending
- 2014-12-12 KR KR1020217017348A patent/KR102453643B1/ko active Active
- 2014-12-12 ES ES14827505T patent/ES2859609T3/es active Active
- 2014-12-12 DK DK14827505.0T patent/DK3082831T3/da active
- 2014-12-12 AU AU2014363270A patent/AU2014363270B2/en active Active
- 2014-12-12 EP EP14827505.0A patent/EP3082831B1/fr active Active
- 2014-12-12 WO PCT/FR2014/053310 patent/WO2015087017A1/fr not_active Ceased
- 2014-12-12 CA CA2930489A patent/CA2930489C/fr active Active
- 2014-12-12 WO PCT/FR2014/053309 patent/WO2015087016A1/fr not_active Ceased
- 2014-12-12 KR KR1020217042008A patent/KR102463677B1/ko active Active
- 2014-12-12 PL PL14827505T patent/PL3082831T3/pl unknown
- 2014-12-12 MX MX2019003446A patent/MX388947B/es unknown
- 2014-12-12 BR BR112016013481-8A patent/BR112016013481A2/pt not_active Application Discontinuation
- 2014-12-12 KR KR1020167013320A patent/KR20160088874A/ko not_active Ceased
-
2018
- 2018-02-23 US US15/903,738 patent/US11266680B2/en active Active
- 2018-04-06 JP JP2018073664A patent/JP2018123153A/ja active Pending
-
2020
- 2020-01-23 AU AU2020200500A patent/AU2020200500B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3082831T3 (da) | Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol | |
| DK2854850T3 (da) | Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom | |
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| DK3366307T3 (da) | Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri | |
| DK2841097T3 (da) | Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom | |
| DK2818481T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK2981274T3 (da) | Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK2935303T3 (da) | 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV | |
| DK2707029T3 (da) | Fremgangsmåder til at behandle eller forebygge kolesterolrelaterede sygdomme | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK2819602T3 (da) | Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme | |
| DK4374873T3 (da) | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande | |
| DK2925327T3 (da) | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression | |
| DK3351630T3 (da) | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af cancer | |
| DK2532680T3 (da) | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK3395353T3 (da) | Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade | |
| DK3693158T3 (da) | Asymmetrisk forarbejdningsfremgangsmåde til krumningsreduktion i laminatstrukturer | |
| DK3508209T3 (da) | Sammensætninger med et svækket newcastle sygdoms-virus og fremgangsmåder til anvendelse til behandling af neoplasi | |
| DK2903967T3 (da) | Acylaminopyrimidinderivater til behandling af virusinfektioner og yderligere sygdomme | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK2967049T3 (da) | Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3581199T3 (da) | Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis | |
| DK2825181T3 (da) | Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom |